Survival data for patients with MDS and ring sideroblasts stratified by the presence or absence of SF3B1 mutation. (A) Survival data for 48 patients with RARS stratified by the presence or absence of SF3B1 mutations. (B) Survival data for 43 patients with RCMD-RS stratified by the presence or absence of SF3B1 mutations.